NextCure Sets CVR Record Date of Dec 8 and Distribution Date of Dec 14 for Avere Merger
NXTC has more than doubled off its 52-week low of $1.55 on light trading volume (0.3× avg).
Summary
NextCure fixed December 8, 2026 as the record date and December 14, 2026 as the expected distribution date for one CVR per share tied to its reverse merger with Avere, with each CVR paying 90% of proceeds from any sale of legacy assets.
Key Events · M&A and Partnerships · NXTC
-
CVR Record and Distribution Dates Fixed
The board set the Pre-Closing Distribution record date at December 8, 2026 and expects the distribution on December 14, 2026, one business day after the anticipated First Effective Time of the Avere merger.
-
CVR Pays 90% of Legacy Asset Proceeds
Each CVR gives holders the right to 90% of gross proceeds from any sale, transfer or license of NextCure's pre-merger legacy assets during the CVR term, less permitted deductions.
-
Conditioned on Merger Closing
Payment of the Pre-Closing Distribution is conditioned on the First Effective Time occurring; shareholders vote on the merger December 9, 2026.
-
Follows October S-4/A Vote Date
Adds distribution mechanics to the December 9, 2026 vote date set in the October 31, 2026 amended S-4; no change to merger terms.
Analysis · NXTC · Life Sciences
The board has now fixed the mechanics of the pre-closing contingent value right distribution tied to the Avere reverse merger. Holders of record on December 8, 2026 receive one CVR per share, with the distribution expected December 14, 2026, one business day after the anticipated First Effective Time. Each CVR pays out 90% of gross proceeds from any sale or license of NextCure's legacy pre-merger assets during the CVR term, net of permitted deductions. Payment is conditioned on the merger closing, and shareholders vote December 9, 2026. For holders, this is the first hard date on the legacy-asset upside that sits alongside the merger consideration — but it is a contractual right to future proceeds, not cash today, and it is worthless if the deal fails or the legacy assets never sell.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXTC was trading at $6.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.5M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.